Scientific American: A Psychedelic May Soon Go to the FDA for Approval to Treat Trauma

Summary: In the February 2022 issue of Scientific American, MAPS-sponsored researcher Jennifer M. Mitchell, Ph.D., takes a deep dive into MAPS’ Phase 3 research of MDMA-assisted therapy for PTSD. Mitchell, lead author of the paper detailing the results of our first Phase 3 study, explains MAPS’ recent success through a historical lens, and looks towards the near future of potential FDA approval.

“As enlightened as this new direction might feel, we must take care to ensure that the zeal of the converted does not color our decision-making,” cautions Mitchell. “We need to take the time to thoroughly investigate these powerful compounds—to understand both their benefits and their shortcomings. Without scientific rigor, the pendulum could swing again.”

Originally appearing here (Archived)